Work

Initial results from a phase II study of nivolumab (NIVO) plus ipilimumab (IPI) for the treatment of metastatic castration-resistant prostate cancer (mCRPC; CheckMate 650).

Year: 2019

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2019.37.7_suppl.142

Authors: Padmanee Sharma, Russell Kent Pachynski, Vivek Narayan, Aude Flechon, Gwenaelle Gravis, Matt D. Galsky, Hakim Mahammedi, Akash Patnaik, Sumit Kumar Subudhi, Marika Ciprotti, Tao Duan, Abdel Saci, Sarah Hu, G. Celine Han, Karim Fizazi

Institutions: The University of Texas MD Anderson Cancer Center, Washington University in St. Louis, Abramson Cancer Center, Centre Léon Bérard, Institut Paoli-Calmettes, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, Centre Jean Perrin, University of Chicago, University of Chicago Medicine Comprehensive Cancer Center, Bristol-Myers Squibb (United States), Institut Gustave Roussy

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2921611058

Cites:

Cited by: 88

Related to: 10